Xiuning Le, MD, PhD, weighs sevabertinib against zongertinib and trastuzumab deruxtecan in HER2-mutant non–small cell lung cancer.

Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.

Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.

Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment selection.

Subcutaneous amivantamab is safer and more convenient for patients compared with the intravenous formulation, according to Misako Nagasaka, MD, PhD.

Mary Jo Lechowicz, MD, discussed how pre-transplant depth of response informs the choice between autologous and allogeneic HSCT in T-cell lymphoma.

Jasmine Zain, MD, described the molecular workup to determine whether a secondary malignancy after CAR T-cell therapy reflects direct insertional mutagenesis.

Misako Nagasaka, MD, PhD, explains how subcutaneous amivantamab’s shorter administration time benefits patients and infusion centers.